Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates

Core Insights - Bristol Myers Squibb (BMY) reported quarterly earnings of $1.63 per share, exceeding the Zacks Consensus Estimate of $1.48 per share, but down from $1.80 per share a year ago, representing an earnings surprise of +10.14% [1] - The company achieved revenues of $12.22 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.33% and up from $11.89 billion year-over-year [2] - Bristol Myers has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was +36.45%, with actual earnings of $1.46 per share compared to an expected $1.07 [1] - The current consensus EPS estimate for the upcoming quarter is $1.61, with projected revenues of $12.08 billion, while the fiscal year estimate is $6.37 EPS on $47.35 billion in revenues [7] Stock Performance and Outlook - Bristol Myers shares have declined approximately 24.7% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions, which can be tracked by investors [5]